```
=> b reg
FILE 'REGISTRY' ENTERED AT 14:27:20 ON 24 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 APR 2008  HIGHEST RN 1016892-81-1
DICTIONARY FILE UPDATES:  23 APR 2008  HIGHEST RN 1016892-81-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l6
L4              STR
```



```
  N~G4~N~G4~N        N~G4~N~G4~N~G4~N
 @41 42 @43 44  45  @46 47 @48 49  50  51  52


  N~G4~N~G4~N~G4~N~G4~N~G4~N~G4~N
 @57 56  55  54  53  58  59  60  61  62  63

VAR G1=10/22/36
VAR G2=O/S
VAR G3=41/43/46/48/57
VAR G4=AK/ID
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  63

STEREO ATTRIBUTES: NONE
L6           23 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED   12203 ITERATIONS                          23 ANSWERS
SEARCH TIME: 00.00.01
```

```
=> b hcap
FILE 'HCAPLUS' ENTERED AT 14:27:28 ON 24 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 24 Apr 2008  VOL 148 ISS 17
FILE LAST UPDATED: 23 Apr 2008  (20080423/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d bib abs hitstr l9 tot
```

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:182730 HCAPLUS

DN 140:235912

TI Preparation of polyamine conjugates with acidic retinoids and their therapeutic applications

IN Papaioannou, Dionysios; Drainas, Dionysios; Tsambaos, Dionysios

PA Greece

SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2004018001	A1	20040304	2002WO-GR0000045	20020822
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU--2002324242	A1	20040311	2002AU-000324242	20020822
EP-----1569694	A1	20050907	2002EP-000758661	20020822
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US-20060189696	A1	20060824	2005US-000549905	20050920
PRAI 2002WO-GR0000045	A	20020822		

OS MARPAT 140:235912

GI



I



AB The present invention discloses preparation of novel polyamine conjugates with acidic retinoids, such as I (R1 = H, Ra; R2 = H, Ra), for their therapeutic use as RNase P inhibitors and anti-inflammatory agents. I have been readily obtained using as key-step the condensation of linear, conformationally restricted, cyclic and branched polyamines or suitably protected derivs. with vitamin A derivs. These compds. inhibit the ribozyme RNase P (RNase P) and the production of interleukin-2 (IL-2) and interferon-γ (INF-γ) by peripheral blood mononuclear cells in vitro. Thus, retinoid analog I [R1 = Ra; R2 = H (II)] was prepared via multistep synthetic sequence starting from I [R1 = H, R2 = COCF3].(CF3CO2H)2 and all-trans-retinoic acid. II was tested for D. discoideum RNase P activity [Ki = 1.1 μM].

IT 666854-46-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(coupling agent; preparation of polyamine conjugates with acidic retinoids and their therapeutic use as RNase inhibitors and anti-inflammatory agents)

RN 666854-46-2 HCAPLUS

CN Retinamide, N,N'-[1,4-butanediylbis(imino-3,1-propanediyl)]bis- (9CI) (CA

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

RN 666854-48-4 HCAPLUS

CN Retinamide, N-[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 666854-49-5 HCAPLUS

CN Retinamide, N,N'-1,4-butanediylbis[N-(3-aminopropyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



IT 666854-45-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of polyamine conjugates with acidic retinoids and their therapeutic use as RNase inhibitors and anti-inflammatory agents)

RN 666854-45-1 HCAPLUS

CN Retinamide, N-[3-[[4-[[3-[[(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-1-oxo-2,4,6,8-nonatetraenyl]amino]propyl]amino]butyl]amino]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



IT 666854-47-3P 666854-48-4P 666854-49-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of polyamine conjugates with acidic retinoids and their therapeutic use as RNase inhibitors and anti-inflammatory agents)

RN 666854-47-3 HCAPLUS

CN Retinamide, N,N'-[1,4-butanediylbis(imino-3,1-propanediyl)]bis-, compd. with 1-hydroxy-2,5-pyrrolidinedione (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 666854-46-2
CMF C50 H78 N4 O2

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



CM 2

CRN 6066-82-6
CMF C4 H5 N O3

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Double bond geometry as shown.

PAGE 1-A



● 2 HCl

PAGE 1-B



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d bib abs hitstr l15 tot
```

L15 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:111563 HCAPLUS

DN 136:322611

TI A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro

AU Baillie, G.; Owens, M. D.; Halbert, G. W.

CS Department of Pharmaceutical Sciences, Strathclyde Institute for Biomedical Sciences, University of Strathclyde, Glasgow, G4 0NR, UK

SO Journal of Lipid Research (2002), 43(1), 69-73
CODEN: JLPRAW; ISSN: 0022-2275

PB Lipid Research, Inc.

DT Journal

LA English

AB A synthetic LDL (sLDL) has been prepared by combining a lipid microemulsion with amphipathic peptides containing the apoprotein B receptor domain. The biol. properties of sLDL have been investigated using the U937 in vitro cell proliferation assay. SLDL exhibits concentration dependent and saturable stimulation of U937 proliferation. By utilizing different amphipathic peptides, variable proliferation is achieved, indicating a specific interaction between sLDL and the U937 LDL receptor are possible. U937 proliferation is reduced by the addition of an anti-LDL receptor antibody, indicating that sLDL is assimilated via the LDL receptor pathway. The behavior of sLDL mimics that of native LDL, and this approach represents a viable technique for the production of an sLDL particle on a large scale for research and general application.

IT 412944-00-4 412944-01-5 412944-02-6
412944-03-7
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(synthetic low d. lipoprotein particle capable of supporting U937 proliferation in vitro)

RN 412944-00-4 HCAPLUS

CN L-Leucine, N-(15-oxoretin-15-yl)-L-leucyl-L-arginyl-L-leucyl-L-threonyl-L-arginyl-L-lysyl-L-arginylglycyl-L-leucyl-L-lysyl-, (3β)-cholest-5-en-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



L15 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



PAGE 2-A



RN 412944-02-6 HCAPLUS

CN L-Serine, N-(15-oxoretin-15-yl)-L-tyrosyl-L-lysyl-L-leucyl-L-α-glutamylglycyl-L-threonyl-L-threonyl-L-arginyl-L-leucyl-L-threonyl-L-arginyl-L-lysyl-L-arginylglycyl-L-leucyl-L-lysyl-L-leucyl-L-alanyl-L-threonyl-L-alanyl-L-leucyl-, 22-(3β)-cholest-5-en-3-yl ester (9CI) (CA INDEX NAME)

L15 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B



PAGE 1-C



RN 412944-01-5 HCAPLUS

CN L-Leucine, N-(15-oxoretin-15-yl)glycyl-L-threonyl-L-threonyl-L-arginyl-L-leucyl-L-threonyl-L-arginyl-L-lysyl-L-arginylglycyl-L-leucyl-L-lysyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L15 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



PAGE 1-C



L15 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-D



PAGE 1-E



RN 412944-03-7 HCAPLUS
CN L-Serine, N-(15-oxoretin-15-yl)-L-tyrosyl-L-lysyl-L-leucyl-L-α-glutamylglycyl-L-threonyl-L-threonyl-L-arginyl-L-leucyl-L-threonyl-L-arginyl-L-lysyl-L-arginylglycyl-L-leucyl-L-lysyl-L-leucyl-L-alanyl-L-threonyl-L-alanyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



L15 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B

PAGE 2-A



PAGE 2-B



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:701805 HCAPLUS
DN 137:67994
TI Physicochemical properties of microemulsion analogues of low density lipoprotein containing amphipathic apoprotein B receptor sequences
AU Owens, M. D.; Baillie, G.; Halbert, G. W.
CS Strathclyde Institute for Biomedical Sciences, Department of Pharmaceutical Sciences, University of Strathclyde, Glasgow, G4 0NR, UK
SO International Journal of Pharmaceutics (2001), 228(1-2), 109-117
CODEN: IJPHDE; ISSN: 0378-5173
PB Elsevier Science B.V.
DT Journal
LA English
AB Low d. lipoprotein (LDL) has been proposed as a drug targeting vector in cancer chemotherapy, however, research has been limited due to the necessity to isolate material from plasma. In this study, the physicochem. properties of synthetic lipid microemulsions containing an amphipathic version of the apoprotein B receptor binding sequence have been examined The effect of peptide sequence length, lipid anchor type and location along with microemulsion lipid composition were investigated via changes in particle size and zeta potential. Size increases were related to the amphipathic peptides lipophilic portion and to a lesser extent by amino acid sequence length. Two lipophilic anchors, retinoic acid and cholesterol, produced large size increases while a single anchor (retinoic acid) did not affect size. The amphipathic peptide reversed measured zeta potential from neg. to pos. values in a concentration-dependent manner. This was related to peptide structure and could be effected by changes in pH, indicating that the peptide was surface located and responsive to the external environment. Alteration of microemulsion lipid composition also affected physicochem. properties but to a lesser degree than changes in the amphipathic peptide. These novel systems may represent a useful synthetic alternative to native LDL for a variety of applications.
IT 412944-00-4 412944-01-5 412944-02-6
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(microemulsion analogs of low d. lipoprotein containing amphipathic apoprotein B receptor sequences)
RN 412944-00-4 HCAPLUS
CN L-Leucine, N-(15-oxoretin-15-yl)-L-leucyl-L-arginyl-L-leucyl-L-threonyl-L-arginyl-L-lysyl-L-arginylglycyl-L-leucyl-L-lysyl-, (3β)-cholest-5-en-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



L15 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B



PAGE 1-C



RN 412944-01-5 HCAPLUS
CN L-Leucine, N-(15-oxoretin-15-yl)glycyl-L-threonyl-L-threonyl-L-arginyl-L-leucyl-L-threonyl-L-arginyl-L-lysyl-L-arginylglycyl-L-leucyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



L15 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A



RN 412944-02-6 HCAPLUS
CN L-Serine, N-(15-oxoretin-15-yl)-L-tyrosyl-L-lysyl-L-leucyl-L-α-glutamylglycyl-L-threonyl-L-threonyl-L-arginyl-L-leucyl-L-threonyl-L-arginyl-L-lysyl-L-arginylglycyl-L-leucyl-L-lysyl-L-leucyl-L-alanyl-L-threonyl-L-alanyl-L-leucyl-, 22-(3β)-cholest-5-en-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



L15 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-E



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B



PAGE 1-C



PAGE 1-D



L15 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1989:628269 HCAPLUS
DN 111:228269
ORPF 111:37837a,37840a
TI Affinity purification of cellular retinoic acid-binding protein on 14-carboxy-13-cis-retinamide-Sepharose 4B
AU Singh, Raj K.; Sani, Brahma P.; Dawson, Marcia I.; Shealy, Y. Fulmer
CS Kettering-Meyer Lab., South. Res. Inst., Birmingham, AL, 35255, USA
SO Biochemical Journal (1989), 262(3), 917-22
CODEN: BIJOAK; ISSN: 0306-3275
DT Journal
LA English
AB A biol. active bifunctional retinoid, Et 14-carboxyretinoate, has been synthesized and shown to bind cellular retinoic acid (RA)-binding protein (CRABP) via its free carboxy group. The synthesis is described of 14-carboxy-13-cis-retinamide-Sepharose 4B, which is an affinity matrix bearing an all-trans-RA moiety, and thus was used to purify and characterize CRABP from chick-embryo skin. An amide bond was first formed between the free carboxy group of the retinoid and a primary amino group of aminohexyl-Sepharose 4B, by reaction with carbodiimide, and the ester group of the resin-bound retinoid was then hydrolyzed in an alkaline medium. Polyacrylamide-gel electrophoresis and fast protein Superose column chromatog. anal. demonstrated that the affinity-purified CRABP (Mr 15,000) was close to electrophoretic homogeneity (>90%) and specifically interacts with RA. By using affinity gel chromatog., conversion of holo-CRABP into apo-CRABP by treatment with p-hydroxymercuribenzoate and a possible involvement of a thiol group in RA binding to CRABP were established. This affinity procedure provides several advantages: (i) 14-carboxy-13-cis-retinamide-Sepharose exhibited high efficiency and selectivity for RA-binding protein (i.e. retinol- or fatty-acid-binding proteins did not bind); (ii) the presence of the amide linkage between the ligand and the matrix makes this affinity resin relatively stable to cytosolic enzymes; and (iii) other RA-binding proteins, e.g. nuclear receptor(s), may be purified.
IT 123757-92-6P
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)
RN 123757-92-6 HCAPLUS
CN Agarose, [6-[(2-(ethoxycarbonyl)-3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]amino]hexyl]carbamimidate (9CI) (CA INDEX NAME)

CM 1

CRN 173430-64-3
CMF C30 H47 N3 O4



CM 2

CRN 9012-36-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
IT 123757-90-4P
RL: PREP (Preparation)
(preparation of, for affinity purification of cellular retinoic acid-binding protein)
RN 123757-90-4 HCAPLUS
CN Agarose, [6-[(2-carboxy-3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]amino]hexyl]carbamimidate (9CI) (CA INDEX NAME)

L15 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

CM 1

CRN 173145-24-9
CMF C28 H43 N3 O4



CM 2

CRN 9012-36-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L15 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 1989:478604 HCAPLUS
Correction of: 1984:552347
DN 111:78604
Correction of: 101:152347
OREF 111:13262h,13263a
TI Peptide and its use
IN Kitaura, Yoshihiko; Nakaguchi, Osamu; Hemmi, Keiji; Aratani, Matsuhiko; Takeno, Hidekazu; Okada, Satoshi; Tanaka, Hirokazu; Hashimoto, Masashi; Kuroda, Yoshio; et al.
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO U.S., 172 pp. Cont.-in-part of U.S. Ser. No. 149,441, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 7

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US-----4322341	A	19820330	1980US-000201241	19801027 <--
US-----4311640	A	19820119	1979US-000093523	19791113 <--
US-----4349466	A	19820914	1981US-000229072	19810128 <--
EP-------50856	A2	19820505	1981EP-000108796	19811023 <--
EP-------50856	A3	19820804		
EP-------50856	B1	19841227		
R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
AT-------10933	T	19850115	1981AT-000108796	19811023 <--
CA-----1241642	A1	19880906	1981CA-000388696	19811026 <--
JP----57134556	A	19820716	1981JP-000172658	19811027 <--
JP----03025437	B	19910405		
US-----4458078	A	19840703	1982US-000377841	19820513 <--
US-----4725582	A	19880216	1982US-000377836	19820513 <--
US-----4801580	A	19890131	1982US-000377931	19820513 <--
US-----4666890	A	19870519	1982US-000380061	19820520 <--
US-----4539155	A	19850903	1983US-000515590	19830721 <--
US-----4749691	A	19880607	1987US-000037470	19870413 <--

PRAI 1979US-000093523 A2 19791113 <--
1980US-000110020 A2 19800107 <--
1980US-000147710 A2 19800508 <--
1980US-000149441 A2 19800513 <--
1978GB-000044346 A 19781114 <--
1979GB-000026705 A 19790731 <--
1979GB-000035401 A 19791011 <--
1979GB-000035730 A 19791015 <--
1979GB-000036000 A 19791017 <--
1979GB-000037343 A 19791029 <--
1979DK-000004722 A 19791107 <--
1979AU-000052759 A 19791113 <--
1979CA-000339737 A 19791113 <--
1979EP-000104470 A 19791114 <--
1979JP-000147275 A 19791114 <--
1979KR-000003985 A 19791114 <--
1980US-000171024 A 19800722 <--
1980US-000201241 A 19801027 <--
1981US-000229072 A 19810128 <--
1981EP-000108796 A 19811023 <--
1982US-000377841 A3 19820513 <--
1982US-000380061 A3 19820520 <--

GI For diagram(s), see printed CA Issue.
AB FR-900156 substance-related peptides I [R = H, acyl; R1 = H, Me, CHMe2, CH2Ph, (un)protected CH2OH; R2 = H, (un)protected CO2H, CONR6R7 [R6 = (un)protected mono- or dicarboxyalkyl; R7 = H, alkyl]; R3, R4 = H (un)protected CO2H, CONR6R7; R5 = H, NH2-protective group; n = 0-2; m = 1-3] were prepared Thus, meso-diaminopimelic acid II (Z = PhCH2O2C, Boc = Me3CO2C) was coupled with H-Gly-OCH2Ph to give peptide III (R8 = Z, R9 = CH2Ph), which was deblocked by hydrogenolysis to give III (R8 = R9 = H). The latter was coupled with Ac-D-Lac-Gly-D-Glu-OCH2Ph (Lac = lactic acid residue) to give peptide IV, which was deblocked by hydrogenolysis, saponification, and acidolysis by CF3CO2H and then treated with 0.1N H2SO4 and aqueous Na metaperiodate to give branched peptide V. Numerous other I analogs were prepared I were shown to enhance immune response and can be used to treat infectious diseases.

L15 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

IT 79335-35-6P 79335-39-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and deblocking of)
RN 79335-35-6 HCAPLUS
CN D-Alanine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-N6-(trifluoroacetyl)-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 79335-39-0 HCAPLUS
CN Glycine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-N6-(trifluoroacetyl)-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 79335-36-7P 79335-40-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 79335-36-7 HCAPLUS
CN D-Alanine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

L15 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 79335-40-3 HCAPLUS
CN Glycine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl]-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L15 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN

AN 1989:193403 HCAPLUS
DN 110:193403
OREF 110:32136h,32137a
TI Manufacture of antibiotic FR-900156 from Streptomyces olivaceogriceus and preparation of its analogs
IN Kitaura, Yoshihiko; Nakaguchi, Osamu; Aratani, Matsuhiko; Takeno, Hidekazu; Okada, Satoshi; Tanaka, Hirokazu; Hashimoto, Masashi; Kuroda, Yoshio; Iguchi, Eiko; et al.
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO U.S., 186 pp. Division of U.S. 4,349,466.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US-----4666890	A	19870519	1982US-000380061	19820520 <--
	DK-----7904722	A	19800515	1979DK-000004722	19791107 <--
	DK------148809	B	19851007		
	DK------148809	C	19860317		
	AU-----7952759	A	19800626	1979AU-000052759	19791113 <--
	AU------529275	B2	19830602		
	US-----4311640	A	19820119	1979US-000093523	19791113 <--
	HU-------23914	A2	19821028	1979HU-FU0000379	19791113 <--
	HU------181434	B	19830728		
	CA-----1143682	A1	19830329	1979CA-000339737	19791113 <--
	JP-----55085552	A	19800627	1979JP-000147275	19791114 <--
	JP-----63018598	B	19880419		
	ES------485962	A1	19800701	1979ES-000485962	19791114 <--
	AT--------1388	T	19820815	1979AT-000104479	19791114 <--
	ES------493817	A1	19810716	1980ES-000493817	19800729 <--
	AU-----8060939	A	19810319	1980AU-000060939	19800730 <--
	AU------544864	B2	19850620		
	US-----4322341	A	19820330	1980US-000201241	19801027 <--
	US-----4349466	A	19820914	1981US-000229072	19810128 <--
	ES------499470	A1	19820816	1981ES-000499470	19810216 <--
	US-----4487763	A	19841211	1982US-000402440	19820728 <--
	US-----4512980	A	19850423	1982US-000402438	19820728 <--
	US--------32992	E	19890718	1984US-000611733	19840518 <--
	US-----4749691	A	19880607	1987US-000037470	19870413 <--
PRAI	1978GB-000044346	A	19781114	<--	
	1979GB-000026705	A	19790731	<--	
	1979GB-000035401	A	19791011	<--	
	1979GB-000035730	A	19791015	<--	
	1979GB-000036000	A	19791017	<--	
	1979GB-000037343	A	19791029	<--	
	1979DK-000004722	A	19791107	<--	
	1979AU-000052759	A	19791113	<--	
	1979CA-000339737	A	19791113	<--	
	1979US-000093523	A2	19791113	<--	
	1979EP-000104470	A	19791114	<--	
	1979JP-000147275	A	19791114	<--	
	1979KR-000003985	A	19791114	<--	
	1980US-000110020	A2	19800107	<--	
	1980US-000147710	A2	19800508	<--	
	1980US-000149441	A2	19800513	<--	
	1980US-000171024	A2	19800722	<--	
	1980US-000201241	A2	19801027	<--	
	1981US-000229072	A3	19810128	<--	
	1979EP-000104479	A	19791114	<--	
	1980GB-000010459	A	19800328	<--	
	1980US-000193453	A3	19801003	<--	
	1982US-000380061	A3	19820520	<--	

GI

L15 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)



AB A new antibiotic FR-900156, D-lactyl-L-alanyl-γ-D-glutamyl-L-mesodiaminopimelylglycine (I; R = D-lactyl), was manufactured by fermentation of Streptomyces olivaceogriceus; its' oligopeptide analogs R1NHCHR4(CH2)mCONHCHR2(CH2)3CHR3NHR5 [II; R1 = alkanoyl; R2,R3 = H, (un)protected CO2H, substituted CONH2; R4 = H, (un)protected CO2H, (un)substituted CONHR2; R5 = H, protecting group; m = 1-3] were prepared I and II showed a protective effect against bacterial infection and enhanced cellular immunity and humoral antibody production A tetrapeptide III (R = H) (662 mg) was dissolved in 50% aqueous Me2CO and NaHCO3 was added to the solution To the mixture was added 408 mg MeCH2COCl at 0° and the resulting mixture was kept at 0° for 1 h, maintaining the pH 7-8 with NaHCO3, to give 400 mg III (R = MeCH2CO). The latter compound was treated with CF3CO2H at ambient temperature to give a white solid which was dissolved in H2O and to the solution was added 0.1 N H2SO4 and aqueous solution of 260 mg NaIO4 with stirring under ice-cooling. The mixture was stirred for 2 h to give, after chromatog. on a macroporous non-ionic adsorption resin HP20 (Mitsubishi Chemical Industry Co., Ltd.), 102 mg I (R = MeCH2CO). II at 1 mg/kg i.p. extended the survival of mice inoculated i.p. with Escherichia coli by 22.2-100%. A hard gelatin capsule containing 300 FR-900156 and 15 mg magnesium stearate was described.

IT 79335-36-7P 118655-15-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as immunostimulant)

RN 79335-36-7 HCAPLUS
CN D-Alanine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 118655-15-5 HCAPLUS
CN D-Norvaline, N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl-5-carbony-, (2S-l')-amide with (R)-6-carboxy-L-lysylglycine, (all-E)- (9CI) (CA INDEX NAME)

L15 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



IT 79335-35-6P 79335-39-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as immunostimulant intermediate)

RN 79335-35-6 HCAPLUS
CN D-Alanine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-N6-(trifluoroacetyl)-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 79335-39-0 HCAPLUS
CN Glycine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-N6-(trifluoroacetyl)-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



L15 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B



L15 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1985:542381 HCAPLUS
DN 103:142381
OREF 103:22822h,22823a
TI Oxazole derivatives
IN Kitaura, Yoshihiko; Kakaguchi, Osamu; Hemmi, Keiji; Acatani, Matsuhiko; Takeno, Hidekazu; Okada, Satashi; Tanaka, Hirakazu; Hashimoto, Masashi; Kuroda, Yashio; et al.
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO U.S., 157 pp. Division of U.S. 4,349,466.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US-4458078	A	19840703	1982US-000377841	19820513	<--
	US-4311640	A	19820119	1979US-000093523	19791113	<--
	HU-23914	A2	19821028	1979HU-FU0000379	19791113	<--
	HU-181434	B	19830728			
	ES-485962	A1	19800701	1979ES-000485962	19791114	<--
	AT-1388	T	19820815	1979AT-000104479	19791114	<--
	ES-493817	A1	19810716	1980ES-000493817	19800729	<--
	AU-8060939	A	19810319	1980AU-000060939	19800730	<--
	AU-544864	B2	19850620			
	US-4322341	A	19820330	1980US-000201241	19801027	<--
	US-4349466	A	19820914	1981US-000229072	19810128	<--
	ES-499470	A1	19820816	1981ES-000499470	19810216	<--
	US-4487763	A	19841211	1982US-000402440	19820728	<--
	US-4512980	A	19850423	1982US-000402438	19820728	<--
	US-4539155	A	19850903	1983US-000515590	19830721	<--
	US-32992	E	19890718	1984US-000611733	19840518	<--
PRAI	1978GB-000044346	A	19781114	<--		
	1979GB-000026705	A	19790731	<--		
	1979GB-000035401	A	19791011	<--		
	1979GB-000035730	A	19791015	<--		
	1979GB-000036000	A	19791017	<--		
	1979GB-000037343	A	19791029	<--		
	1979US-000093523	A2	19791113	<--		
	1980US-000110020	A2	19800107	<--		
	1980US-000147710	A2	19800508	<--		
	1980US-000149441	A2	19800513	<--		
	1980US-000171024	A2	19800722	<--		
	1980US-000201241	A2	19801027	<--		
	1981US-000229072	A3	19810128	<--		
	1979EP-000104479	A	19791114	<--		
	1980GB-000010459	A	19800328	<--		
	1980US-000193453	A3	19801003	<--		
	1982US-000377841	A3	19820513	<--		

OS CASREACT 103:142381
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Oxazoles I (R = protective group, R1 = H or protective group) and II are intermediates for the preparation of pharmacol. active peptides. The synthesis of the peptides (>100) was carried out by various classical methods. Thus, glutamyl(diaminopimelyl)-containing peptide III was prepared from IV (Boc = Me3CO2C) by coupling, hydrogenolysis, deprotection, and hydrazide cleavage reactions. The product peptides have immune response-enhancing activity, mitogenic activity, antiinfection and anticancer activities, etc. (data tabulated).
IT 79335-35-6P 79335-39-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cleavage of trifluoroacetyl group from)
RN 79335-35-6 HCAPLUS
CN D-Alanine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-

L15 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-B



RN 79335-40-3 HCAPLUS
CN Glycine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L15 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
glutamyl]-N6-(trifluoroacetyl)-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 79335-39-0 HCAPLUS
CN Glycine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-N6-(trifluoroacetyl)-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 79335-36-7P 79335-40-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as therapeutic agent)
RN 79335-36-7 HCAPLUS
CN D-Alanine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



L15 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A

PAGE 1-B

L15 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1984:45457 HCAPLUS
DN 100:45457
OREF 100:6859a,6862a
TI Structure-activity and dose-effect relationships of the antagonism of picrotoxin-induced seizures by cholecystokinin, fragments and analogs of cholecystokinin in mice
AU Kadar, T.; Pesti, A.; Penke, B.; Toth, G.; Zarandi, M.; Telegdy, G.
CS Dep. Pathophysiol., Univ. Med. Sch., Szeged, H-6701, Hung.
SO Neuropharmacology (1983), 22(10), 1223-9
CODEN: NEPHBW; ISSN: 0028-3908
DT Journal
LA English
AB I.p. administration of cholecystokinin octapeptide sulfate ester (CCK-8-SE) [25126-32-3] and nonsulfated cholecystokinin octapeptide (CCK-8-NS) [25679-24-7] enhanced the latency of seizures induced by picrotoxin in mice. Expts. with N- and C-terminal fragments revealed that the C-terminal tetrapeptide (CCK-5-8) [1947-37-1] was the active center of the CCK octapeptide mol. The analogs CCK-8-SE and CCK-8-NS (0.2-6.4 μmol/kg) and caerulein (0.1-0.8 μmol/kg) showed bell-shaped dose-effect curves, with the greatest maximum inhibition for CCK-8-NS. CCK-5-8 had weak anticonvulsant activity in comparison to the octapeptides; 3.2 μmol/kg and larger doses of the reference drug, diazepam, totally prevented picrotoxin-induced seizures and mortality. The maximum effect of the peptides tested was less than that of diazepam. Expts. with analogs and derivs. of CCK-5-8 demonstrated that the effectiveness of the β-alanyl derivs. of CCK-5-8 were enhanced and that they were equipotent with CCK-8-SE. Of the CCK-2-8 analogs, Ser(SO3H)7-Ac-CCK-2-8-SE [88457-86-7], Thr(SO3H)7-Ac-CCK-2-8-SE [88457-87-8], and Hyp(SO3H)-Ac-CCK-2-8-SE [88457-88-9] were slightly more active than CCK-8-SE.
IT 88457-74-3
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(anticonvulsant action of, mol. structure in relation to)
RN 88457-74-3 HCAPLUS
CN L-Phenylalaninamide, N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-tryptophyl-L-leucyl-L-α-aspartyl-, (all-E)- (9CI) (CA INDEX NAME)



L15 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 1982:69437 HCAPLUS
DN 96:69437
OREF 96:11429a,11432a
TI Peptides, their pharmaceutical compositions and their intermediates
IN Kitaura, Yoshihiko; Nakaguchi, Osamu; Hemmi, Keiji; Aratani, Matsuhiko; Takeno, Hidekazu; Okada, Satoshi; Tanaka, Hirokazu; Hashimoto, Masashi; Kuroda, Yoshio; et al.
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO Eur. Pat. Appl., 502 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP-------25842	A2	19810401	1980EP-000104502	19800730 <--
	EP-------25842	A3	19820210		
	EP-------25842	B1	19870603		
	R: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	US-----4311640	A	19820119	1979US-000093523	19791113 <--
	AT-------1388	T	19820815	1979AT-000104479	19791114 <--
	DK-----8003272	A	19810201	1980DK-000003272	19800729 <--
	DK------156252	B	19890717		
	DK------156252	C	19891218		
	ES------493817	A1	19810716	1980ES-000493817	19800729 <--
	AU------8060939	A	19810319	1980AU-000060939	19800730 <--
	AU------544864	B2	19850620		
	HU-------28730	A2	19831228	1980HU-000001911	19800730 <--
	HU------188565	B	19860428		
	AT-------27607	T	19870615	1980AT-000104502	19800730 <--
	JP-----56045449	A	19810425	1980JP-000106279	19800731 <--
	JP-----01013463	B	19890306		
	ES------499470	A1	19820816	1981ES-000499470	19810216 <--
	US-----4387763	A	19841211	1982US-000402440	19820728 <--
	US-----4512980	A	19850423	1982US-000402438	19820728 <--
	JP-----63258488	A	19881025	1988JP-000054435	19880308 <--
	JP-----03027560	B	19910416		
	JP-----02288895	A	19901128	1990JP-000095413	19900410 <--
	JP-----06013549	B	19940223		
PRAI	1979GB-000026705	A	19790731	<--	
	1979GB-000035401	A	19791011	<--	
	1979GB-000035730	A	19791015	<--	
	1979GB-000036000	A	19791017	<--	
	1979GB-000037343	A	19791029	<--	
	1979US-000093523	A	19791113	<--	
	1980US-000110020	A	19800107	<--	
	1980US-000147710	A	19800508	<--	
	1980US-000149441	A	19800513	<--	
	1978GB-000044346	A	19781114	<--	
	1979EP-000104479	A	19791114	<--	
	1980GB-000010459	A	19800328	<--	
	1980EP-000104502	A	19800730	<--	
	1980US-000193453	A3	19801003	<--	

OS CASREACT 96:69437; MARPAT 96:69437
GI For diagram(s), see printed CA Issue.
AB FR-900156 substance-related peptides I [R = H, acyl; R1 = H, Me, CHMe2, (un)protected CH2OH, CH2Ph; R3 = H, (un)protected CO2H, CONR6R7 [R6 = (un)protected mono- or dicarboxyalkyl; R7 = H, alkyl]; R3, R4 = H, (un)protected CO2H, CONR6R7]; R5 = H, NH2-protective group; n = 0-2; m = 1-3] were prepared Thus, coupling meso-diaminopimelic acid II (Z = PhCH2O2C, BOC = Me3CO2C) with H-Gly-OCH2Ph by ClCO2CH2CHMe2 gave peptide III (R8 = Z, R9 = CH2Ph), which was deblocked by hydrogenolysis over Pd/C to give III (R8 = R9 = H). The last was coupled with Ac-D-Lac-Gly-D-Glu-OCH2Ph (Lac = lactic acid residue) by ClCO2CH2CHMe3 to give peptide IV, which was saponified, BOC-deblocked, and then treated with 0.1N H2SO4/aqueous Na metaperiodate to give branched peptide V. Numerous other I analogs were prepared I were shown to enhance immune response and can be used to treat infectious diseases.
IT 79335-35-6P 79335-39-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

L15 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
(Reactant or reagent)
(prepn. and deblocking of)
RN 79335-35-6 HCAPLUS
CN D-Alanine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-N6-(trifluoroacetyl)-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 79335-39-0 HCAPLUS
CN Glycine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl]-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-N6-(trifluoroacetyl)-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 79335-36-7P 79335-40-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 79335-36-7 HCAPLUS
CN D-Alanine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

L15 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 79335-40-3 HCAPLUS
CN Glycine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 14:28:05 ON 24 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 14:28:05 ON 24 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:28:05 ON 24 APR 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr l18 tot
```

L18 ANSWER 1 OF 1 USPATFULL on STN
AN 2006:222410 USPATFULL
TI Polyamine conjugates with acidic retinoids and preparation thereof
IN Papaioannou, Dionysios, DEPARTMENT OF CHEMISTRY, UNIVERSITY OF PATRAS, PATRAS, GREECE 26504
Drainas, Dionysios, Patras, GREECE
Tsambaos, Dionysios, Rio Patras, GREECE
PI US-20060189696 A1 20060824
AI 2002US-000549905 A1 20020822 (10)
2002WO-GR0000045 20020822
20050920 PCT 371 date
DT Utility
FS APPLICATION
LREP George B Georgelus, Pkm 143, 152 Congressional Lane, Rockville, MD, 20852, US
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 12 Drawing Page(s)
LN.CNT 832
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Invented are novel polyamine conjugates which have been readily obtained using as key-step the condensation of linear, conformationally restricted, cyclic and branched polyamides or suitably protected derivatives with vitamin A derivatives. These compounds inhibit the ribozyme rivbonuclease P (RNase P) and the production of interleukin-2 (IL-2) amd interferon-γ (INF-γ) by peripheral blood mononuclear cells in vitro.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 666854-46-2P
(coupling agent; preparation of polyamine conjugates with acidic retinoids and their therapeutic use as RNase inhibitors and anti-inflammatory agents)
RN 666854-46-2 USPATFULL
CN Retinamide, N,N'-[1,4-butanediylbis(imino-3,1-propanediyl)]bis- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



IT 666854-47-3P 666854-48-4P 666854-49-5P
(preparation of polyamine conjugates with acidic retinoids and their therapeutic use as RNase inhibitors and anti-inflammatory agents)
RN 666854-47-3 USPATFULL
CN Retinamide, N,N'-[1,4-butanediylbis(imino-3,1-propanediyl)]bis-, compd. with 1-hydroxy-2,5-pyrrolidinedione (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 666854-46-2

L18 ANSWER 1 OF 1 USPATFULL on STN (Continued)
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



IT 666854-45-1
(preparation of polyamine conjugates with acidic retinoids and their therapeutic use as RNase inhibitors and anti-inflammatory agents)
RN 666854-45-1 USPATFULL
CN Retinamide, N-[3-[[4-[[3-[[(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-1-oxo-2,4,6,8-nonatetraenyl]amino]propyl]amino]butyl]amino]propyl]-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



● 2 HCl

PAGE 1-B



L18 ANSWER 1 OF 1 USPATFULL on STN (Continued)
CMF C50 H78 N4 O2

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



CM 2

CRN 6066-82-6
CMF C4 H5 N O3

RN 666854-48-4 USPATFULL
CN Retinamide, N-[3-[[4-[(3-aminopropyl)amino]butyl]amino]propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

RN 666854-49-5 USPATFULL
CN Retinamide, N,N'-1,4-butanediylbis[N-(3-aminopropyl)- (9CI) (CA INDEX NAME)

=> d bib abs hitstr l19 tot

L19 ANSWER 1 OF 4 USPATFULL on STN

AN 2007:256714 USPATFULL
TI Cell Growth
IN Halbert, Gavin William, Glasgow, UNITED KINGDOM
Hayavi, Sima, Glasgow, UNITED KINGDOM
PI US-20070224658 A1 20070927
AI 2004US-000577778 A1 20041028 (10)
2004WO-GB0004560 20041028
20070108 PCT 371 date
PRAI 2003GB-000025085 20031028
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 11 Drawing Page(s)
LN.CNT 980
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to use of peptide containing and peptide free synthetic low density lipoprotein (sLDL) particles as cell growth supplements for the growth of eukaryotic cells, especially mammalian.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 412944-02-6 852357-82-5 852357-84-7
852357-87-0
(sLDL particle containing; use of peptide-containing and peptide-free synthetic low d. lipoprotein particles as cell growth supplement in mammalian cell culture)
RN 412944-02-6 USPATFULL
CN L-Serine, N-(15-oxoretin-15-yl)-L-tyrosyl-L-lysyl-L-leucyl-L-α-glutamylglycyl-L-threonyl-L-threonyl-L-arginyl-L-leucyl-L-threonyl-L-arginyl-L-lysyl-L-arginylglycyl-L-leucyl-L-lysyl-L-leucyl-L-alanyl-L-threonyl-L-alanyl-L-leucyl-, 22-(3β)-cholest-5-en-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



L19 ANSWER 1 OF 4 USPATFULL on STN (Continued)

PAGE 1-B



PAGE 1-C



PAGE 1-D



L19 ANSWER 1 OF 4 USPATFULL on STN (Continued)

PAGE 1-E



RN 852357-82-5 USPATFULL
CN L-Leucine, N-(15-oxoretin-15-yl)-L-leucyl-L-arginyl-L-leucyl-L-threonyl-L-arginyl-L-lysyl-L-arginylglycyl-L-leucyl-L-leucyl-, (3β)-cholest-5-en-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L19 ANSWER 1 OF 4 USPATFULL on STN (Continued)

PAGE 1-C



RN 852357-84-7 USPATFULL
CN L-Leucine, N-(15-oxoretin-15-yl)glycyl-L-threonyl-L-threonyl-L-arginyl-L-leucyl-L-threonyl-L-arginyl-L-lysyl-L-arginylglycyl-L-leucyl-L-lysyl-, (3β)-cholest-5-en-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L19 ANSWER 1 OF 4 USPATFULL on STN (Continued)

PAGE 1-C



PAGE 1-D



RN 852357-87-0 USPATFULL
CN L-Phenylalanine, N2-(15-oxoretin-15-yl)-L-lysyl-L-leucyl-L-α-glutamylglycyl-L-threonyl-L-threonyl-L-arginyl-L-leucyl-L-threonyl-L-arginyl-L-lysyl-L-arginylglycyl-L-leucyl-L-lysyl-L-leucyl-L-alanyl-L-threonyl-L-alanyl-L-leucyl-L-seryl-L-leucyl-L-phenylalanyl-L-leucyl-, 25-(3β)-cholest-5-en-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



L19 ANSWER 1 OF 4 USPATFULL on STN (Continued)

PAGE 1-E



L19 ANSWER 1 OF 4 USPATFULL on STN (Continued)

PAGE 1-B



PAGE 1-C



PAGE 1-D



L19 ANSWER 2 OF 4 USPATFULL on STN
AN 2007:190138 USPATFULL
TI Microparticles
IN Halbert, Gavin William, Glasgow, UNITED KINGDOM
PI US-20070166317 A1 20070719
AI 2004US-0005696650 A1 20040827 (10)
2004WO-GB0003679 20040827
20070205 PCT 371 date
PRAI 2003GB-0000020268 20030829
DT Utility
FS APPLICATION
LREP ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US
CLMN Number of Claims: 18
ECL Exemplary Claims: 1
DRWN 3 Drawing Page(s)
LN.CNT 539
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to microparticles formed from polymer materials and comprising a peptide anchored thereto for binding to a cell surface receptor, for delivering agents to cells and to a method of making such microparticles.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 412944-00-4 412944-03-5 412944-02-6
(microparticles for binding to cell surface receptor)
RN 412944-00-4 USPATFULL
CN L-Leucine, N-(15-oxoretin-15-yl)-L-leucyl-L-arginyl-L-leucyl-L-threonyl-L-arginyl-L-lysyl-L-arginylglycyl-L-leucyl-L-lysyl-, (3β)-cholest-5-en-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L19 ANSWER 2 OF 4 USPATFULL on STN (Continued)

PAGE 1-C



RN 412944-01-5 USPATFULL
CN L-Leucine, N-(15-oxoretin-15-yl)glycyl-L-threonyl-L-threonyl-L-arginyl-L-leucyl-L-threonyl-L-arginyl-L-lysyl-L-arginylglycyl-L-leucyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



L19 ANSWER 2 OF 4 USPATFULL on STN (Continued)

PAGE 1-B



PAGE 2-A



RN 412944-02-6 USPATFULL
CN L-Serine, N-(15-oxoretin-15-yl)-L-tyrosyl-L-lysyl-L-leucyl-L-α-glutamylglycyl-L-threonyl-L-threonyl-L-arginyl-L-leucyl-L-threonyl-L-arginyl-L-lysyl-L-arginylglycyl-L-leucyl-L-lysyl-L-leucyl-L-alanyl-L-threonyl-L-alanyl-L-leucyl-, 22-(3β)-cholest-5-en-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A



L19 ANSWER 2 OF 4 USPATFULL on STN (Continued)

PAGE 1-B



PAGE 1-C



PAGE 1-D



L19 ANSWER 2 OF 4 USPATFULL on STN (Continued)

PAGE 1-E



L19 ANSWER 3 OF 4 USPATFULL on STN

AN 87:36070 USPATFULL

TI Peptide, process for preparation thereof and use thereof

IN Kitaura, Yoshihiko, Sakurai, Japan
Nakaguchi, Osamu, Toyonaka, Japan
Hemmi, Keiji, Suita, Japan
Aratani, Matsuhiko, Suita, Japan
Takeno, Hidekazu, Tenri, Japan
Okada, Satoshi, Takatsuki, Japan
Tanaka, Hirokazu, Takarazuka, Japan
Hashimoto, Masashi, Takarazuka, Japan
Kuroda, Yoshio, Takatsuki, Japan
Iguchi, Eiko, Osaka, Japan
Kohsaka, Masanobu, Sakai, Japan
Aoki, Hatsuo, Ikeda, Japan
Imanaka, Hiroshi, Osaka, Japan

PA Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan (non-U.S. corporation)

PI US-----4666890 19870519

AI 1982US-000380061 19820520 (6)

DCD 19990119

RLI Division of Ser. No. 1981US-000229072, filed on 28 Jan 1981, now patented, Pat. No. US-----4349466 which is a continuation-in-part of Ser. No. 1980US-000201241, filed on 27 Oct 1980, now patented, Pat. No. US-----4322341 which is a continuation-in-part of Ser. No. 1980US-000171024, filed on 22 Jul 1980, now abandoned which is a continuation-in-part of Ser. No. 1980US-000149441, filed on 13 May 1980, now abandoned which is a continuation-in-part of Ser. No. 1980US-000147710, filed on 8 May 1980, now abandoned which is a continuation-in-part of Ser. No. 1980US-000110020, filed on 7 Jan 1980, now abandoned which is a continuation-in-part of Ser. No. 1979US-000093523, filed on 13 Nov 1979, now patented, Pat. No. US-----4311640, issued on 19 Jan 1982

PRAI 1978GB-000044346 19781114
1979GB-000026705 19790731
1979GB-000035401 19791011
1979GB-000035730 19791015
1979GB-000036000 19791017
1979GB-000037343 19791029
1979DK-000004722 19791107
1979AU-000052759 19791113
1979CA-000339737 19791113
1979HU-FU3793993 19791113
1979EP-000104479 19791114
1979JP-000147275 19791114
1979KR-000003985 19791114
1979ES-000485962 19791114
1980CA-000356887 19800722
1980AR-000281972 19800729
1980DK-000003272 19800729
1980ES-000493817 19800729
1980AU-000060939 19800730
1980GR-000062571 19800730
1980MX-000008946 19800730
1980EP-007926705 19800731
1980JP-000106279 19800731
1980KR-000003063 19800731

DT Utility

FS Granted

EXNAM Primary Examiner: Phillips, Delbert R.

LREP Oblon, Fisher, Spivak, McClelland, & Maier

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 9781

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel peptides of enhanced pharmacological activity of the formula: ##STR1## wherein R.sup.1 is alkanoyl;

R.sup.2 and R.sup.q are each hydrogen, carboxy, protected carboxy, or a group of the formula: ##STR2## wherein R.sub.a.sup.2 is mono- or di-carboxy (or protected carboxy) lower alkyl or ar(carboxy or protected carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy,

R.sub.b.sup.2 is hydrogen or lower alkyl;

R.sup.P is hydrogen, carboxy, protected carboxy, with proviso that when one of R.sup.2 and R.sup.q is hydrogen, then the other is carboxy or protected carboxy or a group of the formula: ##STR3## wherein R.sub.a.sup.2 and R.sub.b.sup.2 are each as defined above; R.sup.r is hydrogen or amino protective group;

m is an integer 1 to 3;

or its pharmaceutically acceptable salt.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 79335-36-7P 118655-15-5P
(preparation of, as immunostimulant)

RN 79335-36-7 USPATFULL

CN D-Alanine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 118655-15-5 USPATFULL

CN D-Norvaline, N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl-5-carboxy-, (2S-1')-amide with (R)-6-carboxy-L-lysylglycine, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



L19 ANSWER 3 OF 4 USPATFULL on STN (Continued)

PAGE 1-B



IT 79335-35-6P 79335-39-0P
(preparation of, as immunostimulant intermediate)

RN 79335-35-6 USPATFULL

CN D-Alanine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-N6-(trifluoroacetyl)-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 79335-39-0 USPATFULL

CN Glycine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-N6-(trifluoroacetyl)-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L19 ANSWER 3 OF 4 USPATFULL on STN (Continued)

carboxy) lower alkyl whose aryl moiety may be substituted by hydroxy,

R.sub.b.sup.2 is hydrogen or lower alkyl;

R.sup.P is hydrogen, carboxy, protected carboxy, with proviso that when one of R.sup.2 and R.sup.q is hydrogen, then the other is carboxy or protected carboxy or a group of the formula: ##STR3## wherein R.sub.a.sup.2 and R.sub.b.sup.2 are each as defined above; R.sup.r is hydrogen or amino protective group;

m is an integer 1 to 3;

or its pharmaceutically acceptable salt.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 79335-36-7P 118655-15-5P
(preparation of, as immunostimulant)

RN 79335-36-7 USPATFULL

CN D-Alanine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 1-B

RN 118655-15-5 USPATFULL

CN D-Norvaline, N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl-5-carboxy-, (2S-1')-amide with (R)-6-carboxy-L-lysylglycine, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A

L19 ANSWER 4 OF 4 USPATFULL on STN

AN 84:37299 USPATFULL

TI Oxazole derivatives

IN Kitaura, Yoshihiko, Sakurai, Japan
Nakaguchi, Osamu, Toyonaka, Japan
Hemmi, Keiji, Suita, Japan
Aratani, Matsuhiko, Suita, Japan
Takeno, Hidekazu, Tenri, Japan
Okada, Satoshi, Takatsuki, Japan
Tanaka, Hirokazu, Takarazuka, Japan
Hashimoto, Masashi, Takarazuka, Japan
Kuroda, Yoshio, Takatsuki, Japan
Iguchi, Eiko, Osaka, Japan
Kohsaka, Masanobu, Sakai, Japan
Aoki, Hatsuo, Ikeda, Japan
Imanaka, Hiroshi, Osaka, Japan

PA Fujisawa Pharmaceutical Company, Ltd., Osaka, Japan (non-U.S. corporation)

PI US-----4458078 19840703

AI 1982US-000377841 19820513 (6)

RLI Division of Ser. No. 1981US-000229072, filed on 28 Jan 1981, now patented, Pat. No. US-----4349466 which is a continuation-in-part of Ser. No. 1980US-000201241, filed on 27 Oct 1980, now patented, Pat. No. US-----4322341 which is a continuation-in-part of Ser. No. 1980US-000171024, filed on 22 Jul 1980, now abandoned which is a continuation-in-part of Ser. No. 1980US-000149441, filed on 13 May 1980, now abandoned which is a continuation-in-part of Ser. No. 1980US-000147710, filed on 8 May 1980, now abandoned which is a continuation-in-part of Ser. No. 1980US-000110020, filed on 7 Jan 1980, now abandoned which is a continuation-in-part of Ser. No. 1979US-000093523, filed on 13 Nov 1979, now patented, Pat. No. US-----4311640, issued on 19 Jan 1982

PRAI 1978GB-000044346 19781114
1979GB-000026605 19790731
1979GB-000035401 19791011
1979GB-000035730 19791015
1979GB-000036000 19791017
1979GB-000037343 19791029

DT Utility

FS Granted

EXNAM Primary Examiner: Phillips, Delbert R.; Assistant Examiner: Moezie, F. T.

LREP Oblon, Fisher, Spivak, McClelland & Maier

CLMN Number of Claims: 2

ECL Exemplary Claim: 1,2

DRWN 1 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 8654

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel intermediates for the preparation of peptides of pharmacological activity, said intermediates being of the formulas: ##STR1## wherein R.sub.2.sup.r is amino protective group and

Y is hydrogen or amino protective group; and : ##STR2##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 79335-35-6P 79335-39-0P
(preparation and cleavage of trifluoroacetyl group from)

RN 79335-35-6 USPATFULL

CN D-Alanine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-N6-(trifluoroacetyl)-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



L19 ANSWER 4 OF 4 USPATFULL on STN (Continued)

PAGE 1-B



RN 79335-39-0 USPATFULL
CN Glycine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-N6-(trifluoroacetyl)-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 79335-36-7P 79335-40-3P
(preparation of, as therapeutic agent)
RN 79335-36-7 USPATFULL
CN D-Alanine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 79335-40-3 USPATFULL
CN Glycine, N-[(R)-6-carboxy-N2-[N-[N-[3,7-dimethyl-1-oxo-9-(2,6,6-trimethyl-

L19 ANSWER 4 OF 4 USPATFULL on STN (Continued)
1-cyclohexen-1-yl)-2,4,6,8-nonatetraenyl]-L-alanyl]-D-γ-glutamyl]-L-lysyl]-, (all-E)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



```
=> d his

     (FILE 'HOME' ENTERED AT 14:05:23 ON 24 APR 2008)

     FILE 'HCAPLUS' ENTERED AT 14:05:37 ON 24 APR 2008
L1            1 US20060189696/PN

     FILE 'REGISTRY' ENTERED AT 14:05:52 ON 24 APR 2008

     FILE 'HCAPLUS' ENTERED AT 14:05:52 ON 24 APR 2008
L2              TRA L1 1- RN :       39 TERMS

     FILE 'REGISTRY' ENTERED AT 14:05:53 ON 24 APR 2008
L3           39 SEA L2

     FILE 'REGISTRY' ENTERED AT 14:06:05 ON 24 APR 2008
L4              STR
L5            2 L4
L6           23 L4 FULL
                SAV TEM L6 J905C1/A
L7            5 L6 AND L3
L8           18 L6 NOT L7

     FILE 'HCAPLUS' ENTERED AT 14:15:06 ON 24 APR 2008
L9            1 L7
L10          11 L8
L11           8 L10 AND (PD<=20020822 OR AD<=20020822 OR PRD<=20020822)
L12           7 L10 AND PD<=20010822
L13           3 L10 NOT L11-12
                SEL HIT RN L13

     FILE 'REGISTRY' ENTERED AT 14:19:14 ON 24 APR 2008
L14           6 E1-6

     FILE 'HCAPLUS' ENTERED AT 14:21:21 ON 24 APR 2008
L15           8 L11-12
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 14:21:39 ON 24 APR 2008
L16          12 E7-18

     FILE 'HCAOLD' ENTERED AT 14:24:20 ON 24 APR 2008
L17           0 L6

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 14:24:32 ON 24 APR 2008
L18           1 L7
L19           4 L8
```